GLP-1 drugs have become a game-changer in treating obesity and type 2 diabetes, forecast to reach a $100 billion market value by 2030. However, their rapid rise raises important questions about resource allocation in pharmaceutical development and manufacturing, as well
Jon Reed, Head of Strategic Business Planning at Recipharm, recently shared insights into the CDMO’s latest innovations and market strategies. Speaking to the PharmaSource podcast at CPHI Milan, Jon explains how Recipharm, one of the largest CDMOs in the industry
What happened? Catalent, involved in producing Novo Nordisk’s top-selling GLP-1 obesity drug Wegovy, has over 50 sites globally. The acquisition follows Catalent’s strategic review due to declining revenue and issues at major manufacturing sites. The purchase price of $63.5 per
The diabetes and obesity market is expanding rapidly, with GLP-1 agonists a key medication that is proven to lower blood sugar levels, they also suppress appetite and reduce calorie intake. J.P. Morgan Research forecasts that the GLP-1 market will exceed
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
